Compare SWBI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | PRTC |
|---|---|---|
| Founded | 1852 | 2015 |
| Country | United States | United States |
| Employees | N/A | 90 |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.2M | 400.2M |
| IPO Year | 2000 | N/A |
| Metric | SWBI | PRTC |
|---|---|---|
| Price | $14.82 | $18.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 595.8K | 3.7K |
| Earning Date | 03-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | N/A |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $297.00 | ★ $8.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $14.50 |
| 52 Week High | $15.40 | $19.92 |
| Indicator | SWBI | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 61.58 | 69.60 |
| Support Level | $13.80 | $18.07 |
| Resistance Level | $15.24 | $19.16 |
| Average True Range (ATR) | 0.44 | 0.44 |
| MACD | -0.08 | 0.37 |
| Stochastic Oscillator | 76.84 | 98.36 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.